Acceptability of a new 4-in-1 Abacavir/Lamivudine/Lopinavir/Ritonavir paediatric fixed-dose combination: the caregiver–child dyads’ perspective

Acceptability of a new 4-in-1 Abacavir/Lamivudine/Lopinavir/Ritonavir paediatric fixed-dose combination: the caregiver–child dyads’ perspective

Background: Worldwide, 1.7 million children younger than 15 years were living with HIV in 2021. Only 52% of them had access to antiretrovirals (ARVs). Lack of age-appropriate ARV formulations (i.e. easy to swallow for young infants, acceptable taste) remains the main obstacle to the access to ARVs....

Full description

Bibliographic Details
Main Authors: Anke Rotsaert, Collin Ogara, Juliet Mwanga-Amumpaire, Adeodata R. Kekitiinwa, Victor Musiime, Elizabeth Najjingo, Grace P. Kisitu, Rashidah Nazzinda, Esther Nambi, Janice Lee, Mariama Diallo, Flavia Kyomuhendo, Moses Waweru, Isabelle Andrieux-Meyer, Christiana Nöstlinger
Format: Article
Language:English
Published: SAGE Publishing 2023-03-01
Series:Therapeutic Advances in Infectious Disease
Online Access:https://doi.org/10.1177/20499361231159993

Internet

https://doi.org/10.1177/20499361231159993

Similar Items